Jon Hollick

Company: Breakpoint Therapeutics

Job title: Managing Director & Head of Research

Seminars:

Next Generation DDR/Synthetic Lethality Targets: Mining DNA Metabolism for Gold 2:25 pm

Approaches to drug discovery Overview of Polymerase theta as a tumour selective drug target Exploiting cancer replication stress: spotlight on WRN helicaseRead more

day: Day One